25 related articles for article (PubMed ID: 38433053)
1. Loss of Heterozygosity at Chromosome 16q Is a Negative Prognostic Factor in Korean Pediatric Patients with Favorable Histology Wilms Tumor: A Report of the Korean Pediatric Hematology Oncology Group (K-PHOG).
Park JE; Noh OK; Lee Y; Choi HS; Han JW; Hahn SM; Lyu CJ; Lee JW; Yoo KH; Koo HH; Jeong SY; Sung KW
Cancer Res Treat; 2020 Apr; 52(2):438-445. PubMed ID: 31505910
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532.
Evageliou N; Renfro LA; Geller J; Perlman E; Kalapurakal J; Paulino A; Dix D; Eklund MJ; Murphy AJ; Romao RLP; Ehrlich PF; Varela CR; Vallance K; Fernandez CV; Dome JS; Mullen EA
Cancer; 2024 Mar; 130(5):792-802. PubMed ID: 37902955
[TBL] [Abstract][Full Text] [Related]
3. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
[TBL] [Abstract][Full Text] [Related]
4. Profiling Loss of Heterozygosity Patterns in a Cohort of Favorable Histology Nephroblastoma Egyptian Patients: What is Consistent With the Rest of the World.
Fawzy M; Bahanassy A; Samir A; Hafez H
Pediatr Hematol Oncol; 2015; 32(8):548-56. PubMed ID: 26390800
[TBL] [Abstract][Full Text] [Related]
5. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
[TBL] [Abstract][Full Text] [Related]
6. [Correlation of 1p/16q loss of heterozygosity and 1p gain with clinicopathological characteristics and prognosis in Wilms tumor].
Jia C; Yao XF; Zhang M; Guan XX; Wang JW; Song HC; He LJ
Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):257-263. PubMed ID: 38433053
[No Abstract] [Full Text] [Related]
7. New approaches to risk stratification for Wilms tumor.
Nelson MV; van den Heuvel-Eibrink MM; Graf N; Dome JS
Curr Opin Pediatr; 2021 Feb; 33(1):40-48. PubMed ID: 33394739
[TBL] [Abstract][Full Text] [Related]
8. [Molecular genetic progression on nasopharyngeal carcinoma].
Shao JY; Zeng WF; Zeng YX
Ai Zheng; 2002 Jan; 21(1):1-10. PubMed ID: 12500388
[TBL] [Abstract][Full Text] [Related]
9. Loss of heterozygosity mapping in Wilms tumor indicates the involvement of three distinct regions and a limited role for nondisjunction or mitotic recombination.
Coppes MJ; Bonetta L; Huang A; Hoban P; Chilton-MacNeill S; Campbell CE; Weksberg R; Yeger H; Reeve AE; Williams BR
Genes Chromosomes Cancer; 1992 Nov; 5(4):326-34. PubMed ID: 1283321
[TBL] [Abstract][Full Text] [Related]
10. Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor.
Dome JS; Mullen EA; Dix DB; Gratias EJ; Ehrlich PF; Daw NC; Geller JI; Chintagumpala M; Khanna G; Kalapurakal JA; Renfro LA; Perlman EJ; Grundy PE; Fernandez CV
J Natl Compr Canc Netw; 2021 Aug; 19(8):978-985. PubMed ID: 34416705
[TBL] [Abstract][Full Text] [Related]
11. Risk stratification for wilms tumor: current approach and future directions.
Dome JS; Perlman EJ; Graf N
Am Soc Clin Oncol Educ Book; 2014; ():215-23. PubMed ID: 24857079
[TBL] [Abstract][Full Text] [Related]
12. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration.
Dome JS; Graf N; Geller JI; Fernandez CV; Mullen EA; Spreafico F; Van den Heuvel-Eibrink M; Pritchard-Jones K
J Clin Oncol; 2015 Sep; 33(27):2999-3007. PubMed ID: 26304882
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
